Experience with early use of certolizumab pegol in able-bodied patients with axial spondyloarthritis in the framework of a model for clinical statistical groups
https://doi.org/10.14412/1996-7012-2020-3-97-101
Abstract
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease that affects predominantly the sacroiliac joints and spine. The main goal of axSpA therapy is to slow down and prevent structural damages that become a main cause of disability in able-bodied patients. Timely diagnosis and early prescription of biological agents can slow down the progression of the disease. The paper presents the experience in using the tumor necrosis factor-α inhibitor certolizumab pegol (CP) in a young female patient with early axSpA, who receives the drug within the framework of a model for clinical statistical groups (CSG) in the Kaliningrad Region. The high efficiency of CP and the possibility of using the latter within the CSG tariffs allow the drug to be prescribed for early-stage axSpA. The absence of an Fc-fragment in the molecular structure of CP provides additional opportunities for reproductive-aged female patients who can use the drug during the planning stage, pregnancy, and lactation.
About the Author
Yu. Yu. Grabovetskaya
Immanuel Kant Baltic Federal University
Russian Federation
Russian Federation
Yulia Yuryevna Grabovetskaya
14, Aleksandr Nevsky St., Kaliningrad 236016
References
1. Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60. (In Russ.). doi: 10.14412/1995-4484-2015-657-660
2. Dubinina TV, Erdes ShF. Reasons for late diagnosis of ankylosing spondylitis in clinical practice. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2010;48(2):43-8. (In Russ.). doi: 10.14412/1995-4484-2010-1415
3. Rumyantseva DG, Erdes ShF. Axial spondyloarthritis: a current look at the concept and evolution of the disease. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(4):4-10. (In Russ.). doi: 10.14412/1996-7012-2019-4-4-10
4. Lila AM, Dreval' RO, Inamova OV, et al. Medical and economic analysis of the impact of rheumatoid disease-associated disability on the country's economy in terms of implementation of pension reforms. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(4):18-25. (In Russ.). doi: 10.14412/1996-7012-2019-4-18-25
5. Volnukhin EV, Galushko EA, Bochkova AG, et al. Clinical diversity of ankylosing spondylitis in the real practice of a rheumatologist in Russia (Part 1). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(2):44-9. (In Russ.). doi: 10.14412/1995-4484-2012-1272
6. Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015 Aug 15;1(Suppl 1): e000053. doi: 10.1136/rmdopen-2015000053. eCollection 2015.
7. Lopez-Medina C, Ramiro S, van der Heijde D, et al. Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019 Nov 21; 5(2):e001108. doi: 10.1136/rmdopen-2019001108. eCollection 2019.
8. Van der Heijde D, Ramiro S, Landew ОR, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978-91. doi: 10.1136/annrheumdis2016-210770. Epub 2017 Jan 13.
9. Ministry of health of the Russian Federation. Clinical recommendations. Ankylosing spondylitis (KR 252).
10. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.
11. Maksymowych WP, Morency N, ConnerSpady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013 Jan;72(1):23-8. doi: 10.1136/annrheumdis-2011-200859. Epub 2012 May 5.
12. Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther. 2014; 16(3):109. doi: 10.1186/ar4561.
13. https://acrabstracts.org/abstract/earliertreatment-of-non-radiographic-axialspondyloarthritis-with-certolizumab-pegolresults-in-improved-clinical-and-patientreported-outcomes/
14. Van der Heijde D, Baraliakos X, Hermann KA, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018 May;77(5):699-705. doi: 10.1136/annrheumdis-2017-212377. Epub 2018 Jan 17.
15. Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014 Jun;73(6):1107-13. doi: 10.1136/annrheumdis-2012-203075. Epub 2013 May 3.
16. Baraliakos X, Braun J, Deodhar A, et al. Secukinumad demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Ann Rheum Dis. 2018;77:997-8. doi:10.1136/annrheumdis-2018-eular.1396
17. Maas F, Arends S, Brouwer E, et al. Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1011-1019. doi: 10.1002/acr.23097. Epub 2017 Jun 9.
18. Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018 Jan;77(1):63-9. doi: 10.1136/annrheumdis2017-211544. Epub 2017 Sep 22.
19. Poddubnyy D, Protopopov M, Haibel H, et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis. 2016 Dec;75(12):2114-18. doi: 10.1136/annrheumdis-2016-209209. Epub 2016 Apr 28.
20. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007 Jul;66(7):910-5. doi: 10.1136/ard.2006.066415. Epub 2007 Feb 28.
21. Dougados M, Sepriano A, Molto A, et al. Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Ann Rheum Dis. 2017 Nov;76(11):1823-28. doi: 10.1136/annrheumdis-2017-211596. Epub 2017 Jul 6.
22. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/ Spondylitis Association of America/ Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016 Feb;68(2):282-98. doi: 10.1002/art.39298. Epub 2015 Sep 24.
23. Wang R, Dasgupta A, Ward MM. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis. J Rheumatol. 2018 Apr;45(4): 481-90. doi: 10.3899/jrheum.170224. Epub 2018 Jan 15.
24. Callhoff J, Sieper J, WeiІ A, et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015 Jun;74(6):1241-8. doi: 10.1136/annrheumdis-2014-205322. Epub 2014 Apr 9.
25. Hou LQ, Jiang GX, Chen YF, et al. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials. Clin Rev Allergy Immunol. 2018 Apr;54(2): 234-43. doi: 10.1007/s12016-017-8623-6.
26. Bonovas S, Minozzi S, Lytras T, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54. doi: 10.1080/14740338.2016.1238458.
27. Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783.
28. Lila AM. A healthy and nuclear family of a patient with inflammatory disease: topical issues and ways of their solution. What can modern medicine offer? Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(1):93-100. (In Russ.). doi: 10.14412/1996-7012-2018-1-93-100
29. Kavanaugh A, Cush JJ, Ahmed MS, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken). 2015 Mar;67(3):313-25. doi: 10.1002/acr.22516.
30. Mariette X, FЪrger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228-33. doi: 10.1136/annrheumdis-2017-212196. Epub 2017 Oct 13.
31. Methodological recommendations on ways to pay for medical care at the expense of mandatory medical insurance (Ministry of health of the Russian Federation Federal Fund for mandatory medical insurance. Protocol of the meeting dated 18.12.15 №06/11/20).
32. Lukas C, Cyteval C, Dougados M, Weber U. MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations 'Not everything that glisters is gold (standard)'. RMD Open. 2018 Jan 12;4(1):e000586. doi: 10.1136/rmdopen-2017-000586. eCollection 2018.
33. De Winter J, de Hooge M, van de Sande M, et al. Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. Arthritis Rheumatol. 2018 Jul;70(7):1042-48. doi: 10.1002/art.40475. Epub 2018 May 23.
34. Danve A, Deodhar A. Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities. Clin Rheumatol. 2019 Mar;38(3):625-34. doi: 10.1007/s10067018-4397-3. Epub 2018 Dec 26.
35. Deodhar A, Gensler LS, Kay J, et al. A Fifty-Two-Week, Randomized, PlaceboControlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 Jul;71(7):1101-11. doi: 10.1002/art.40866. Epub 2019 May 28.
Review
For citations:
Grabovetskaya YY. Experience with early use of certolizumab pegol in able-bodied patients with axial spondyloarthritis in the framework of a model for clinical statistical groups. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(3):97-101. (In Russ.) https://doi.org/10.14412/1996-7012-2020-3-97-101
Views:
756
Email this article 